• T-5224 (C-Fos/AP-1 Inhibitor): New Horizons in Translational

  2026-06-22

  This article examines how T-5224, a highly selective C-Fos/AP-1 inhibitor from APExBIO, is redefining the landscape for translational researchers exploring inflammation, arthritis, and malignancy. By integrating mechanistic insights—such as T-5224’s role in inducing ferroptosis via PI3K/AKT inhibition in multiple myeloma—with strategic guidance for protocol design and emergent disease models, we illuminate how this compound bridges mechanistic rigor and clinical aspiration. This piece advances the discussion by synthesizing recent breakthroughs and providing actionable next steps for the translational community.

• Exo1 (methyl 2-(4-fluorobenzamido)benzoate): Precision in Me

  2026-06-22

  Exo1 delivers rapid, selective inhibition of exocytic membrane traffic, enabling advanced studies of ARF1-driven Golgi-ER dynamics and extracellular vesicle biogenesis. Its unique mechanism—distinct from classic agents—empowers high-fidelity exocytosis assays and tumor microenvironment research.

• Oxidation Alters Hazelnut Protein Gel Properties and Functio

  2026-06-21

  This study systematically investigated how different oxidative agents, including AAPH, malondialdehyde, and hydrogen peroxide, impact the functional and gel properties of hazelnut proteins. The findings reveal that both the type and concentration of oxidant distinctly modulate protein solubility, emulsifying activity, and gel structure—providing mechanistic insight relevant for food processing and oxidative stress modeling.

• AMPK–SQSTM1 Feedback Unveils Dual Stress Response in NSCLC

  2026-06-20

  This study uncovers a double-positive feedback loop between AMPK and SQSTM1/p62 that enables synergistic activation of AMPK and NFE2L2/NRF2 under metabolic stress in non-small cell lung cancer. The findings clarify how cancer cells coordinate antioxidant defenses and metabolic adaptation, providing a mechanistic rationale for co-occurring STK11 and KEAP1 mutations.

• SPP1 Drives M2 Macrophage Infiltration in ESCC via PI3K/AKT

  2026-06-19

  This study elucidates how SPP1 fosters the progression of oesophageal squamous cell carcinoma (ESCC) by recruiting and polarizing macrophages toward a pro-tumorigenic M2 phenotype via the CD44/PI3K/AKT signaling pathway. The findings provide mechanistic insight into tumor–immune cell crosstalk and highlight SPP1 as a promising therapeutic target, with implications for modulating the tumor microenvironment in ESCC.

• Purmorphamine: Advanced Smoothened Agonist Use in Research

  2026-06-19

  Purmorphamine stands out as a powerful Smoothened agonist, enabling researchers to modulate Hedgehog signaling for both osteoblast differentiation and sensory biology studies. This article delivers actionable protocols, insight from new olfactory research, and optimization tips for applied experimental success.

• Technical Guidance for Angiotensin I/II (1-5) in RAS Assays

  2026-06-18

  Angiotensin I/II (1-5) enables targeted modeling of blood pressure regulation and aldosterone signaling in cardiovascular and renal research workflows. It is not recommended for studies outside the renin-angiotensin system or unrelated peptide signaling pathways. Appropriate use requires strict adherence to solubility and storage protocols.

• Clodronate Liposomes: Precision In Vivo Macrophage Depletion

  2026-06-18

  Clodronate Liposomes from APExBIO empower researchers to dissect macrophage function in complex in vivo models with highly selective depletion. This article delivers actionable protocol enhancements, troubleshooting strategies, and insights from recent single-cell studies to optimize immune cell modulation and polarization assays.

• TMEM16F Lipid Scrambling Modulates Ferroptosis and Tumor Imm

  2026-06-17

  The referenced study uncovers TMEM16F-mediated lipid scrambling as a critical regulator suppressing ferroptosis by remodeling plasma membrane phospholipids. Inhibiting TMEM16F not only potentiates ferroptotic cell death but also enhances tumor immune rejection, offering new mechanistic insight and therapeutic potential for cancer immunotherapy.

• Guidelines for Diagnosis and Treatment of Cutaneous Candidia

  2026-06-17

  This article analyzes the clinical guideline paper by Kato (2009), which provides a comprehensive framework for the diagnosis and topical management of mucocutaneous candidiasis, particularly focusing on the role of imidazole antifungals such as Neticonazole Hydrochloride. The review highlights diagnostic strategies, classification schemes, and evidence-backed topical therapy, with implications for translational research and experimental modeling.

• DIDS in Metastatic Reprogramming: Mechanistic Insights and A

  2026-06-16

  Explore how DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid) uniquely modulates chloride and TRPV1 channels, with implications for metastatic reprogramming and neuroprotection. This article offers an in-depth, evidence-based analysis not found in standard overviews.

• Generation of Functional Hepatobiliary Organoids from hiPSCs

  2026-06-16

  Wu et al. established a robust protocol for producing hepatobiliary organoids from human induced pluripotent stem cells (hiPSCs), recapitulating key aspects of liver development without genetic modification or exogenous cell input. This model offers a significant advance for studying human liver organogenesis and facilitates drug discovery and disease modeling in vitro.

• Trelagliptin Promotes Osteoblastic Differentiation via RUNX2

  2026-06-15

  The reference study demonstrates that Trelagliptin, a DPP-4 inhibitor, enhances osteoblastic differentiation in MC3T3-E1 cells through upregulation of RUNX2 via AMPK signaling. These findings introduce a potential therapeutic avenue for osteoporosis and highlight the importance of precise cell preparation in translational bone research.

• Toremifene in Breast Cancer: 20 Years of Clinical Insights

  2026-06-15

  This review analyzes two decades of clinical data on toremifene, a selective estrogen receptor modulator (SERM), for the treatment of hormone-sensitive breast cancer. The paper highlights efficacy, safety, and the evolving context of endocrine therapies, with implications for biomarker-driven and personalized approaches in breast cancer research.

• P2RX1 Drives Mitochondrial Apoptosis in Ph+ ALL via Ca2+/CaM

  2026-06-14

  This study uncovers how P2RX1 overexpression sensitizes Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) cells to mitochondrial apoptosis by modulating intracellular calcium and suppressing PI3K/Akt signaling. The findings provide mechanistic insight into apoptosis regulation in TKI-resistant leukemia and highlight potential therapeutic targets.

14470 records 1/965 page Next 12345 下5页 Last page